At the time of writing, Akero Therapeutics Inc [AKRO] stock is trading at $51.84, up 2.49%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AKRO shares have gain 5.30% over the last week, with a monthly amount glided 107.19%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Akero Therapeutics Inc [NASDAQ: AKRO] stock has seen the most recent analyst activity on January 30, 2025, when BofA Securities upgraded its rating to a Buy and also boosted its price target to $63 from $35. Previously, H.C. Wainwright reaffirmed its Buy rating on January 27, 2025, and elevated its price target to $72. On November 18, 2024, Citigroup initiated with a Buy rating and assigned a price target of $65 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $69 as its price target on September 19, 2023. UBS started tracking with a Buy rating for this stock on August 28, 2023, and assigned it a price target of $83. In a note dated January 27, 2023, Morgan Stanley upgraded an Overweight rating on this stock and boosted its target price from $40 to $65.
For the past year, the stock price of Akero Therapeutics Inc fluctuated between $17.86 and $58.40. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $51.84 at the most recent close of the market. An investor can expect a potential drop of -3.55% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -948.14%, Pretax Profit Margin comes in at -835.29%, and Net Profit Margin reading is -835.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.33 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 51.04 points at the first support level, and at 50.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 52.69, and for the 2nd resistance point, it is at 53.54.
Ratios To Look Out For
It is important to note that Akero Therapeutics Inc [NASDAQ:AKRO] has a current ratio of 17.25. Further, the Quick Ratio stands at 17.25, while the Cash Ratio is 7.3.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on Feb 18 ’25 when 10000.0 shares were sold. President and CEO, Cheng Andrew completed a deal on Feb 10 ’25 to sell 30000.0 shares. Meanwhile, Director Graham G. Walmsley bought 0.2 million shares on Jan 30 ’25.
